Immune Response BioPharma, Inc.

Quick facts

Phase 3 pipeline

• IR103 · Oncology
  IR103 is an immunotherapeutic agent designed to modulate immune response, likely through activation or enhancement of anti-tumor immunity.

Phase 2 pipeline

• IFA Incomplete Freund's Adjuvant
• NeuroVax

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Immune Response BioPharma, Inc. portfolio CI brief
• Immune Response BioPharma, Inc. pipeline updates RSS